189 related articles for article (PubMed ID: 27706621)
1. Low levels of serum miR-99a is a predictor of poor prognosis in breast cancer.
Li J; Song ZJ; Wang YY; Yin Y; Liu Y; Nan X
Genet Mol Res; 2016 Aug; 15(3):. PubMed ID: 27706621
[TBL] [Abstract][Full Text] [Related]
2. MicroRNA-99a inhibits tumor aggressive phenotypes through regulating HOXA1 in breast cancer cells.
Wang X; Li Y; Qi W; Zhang N; Sun M; Huo Q; Cai C; Lv S; Yang Q
Oncotarget; 2015 Oct; 6(32):32737-47. PubMed ID: 26417931
[TBL] [Abstract][Full Text] [Related]
3. Decreased expression of microRNA-124 is an independent unfavorable prognostic factor for patients with breast cancer.
Dong LL; Chen LM; Wang WM; Zhang LM
Diagn Pathol; 2015 Apr; 10():45. PubMed ID: 25924779
[TBL] [Abstract][Full Text] [Related]
4. Prognostic Value of a BCSC-associated MicroRNA Signature in Hormone Receptor-Positive HER2-Negative Breast Cancer.
Gong C; Tan W; Chen K; You N; Zhu S; Liang G; Xie X; Li Q; Zeng Y; Ouyang N; Li Z; Zeng M; Zhuang S; Lau WY; Liu Q; Yin D; Wang X; Su F; Song E
EBioMedicine; 2016 Sep; 11():199-209. PubMed ID: 27566954
[TBL] [Abstract][Full Text] [Related]
5. Circulating miR-99a-5p Expression in Plasma: A Potential Biomarker for Early Diagnosis of Breast Cancer.
Garrido-Cano I; Constâncio V; Adam-Artigues A; Lameirinhas A; Simón S; Ortega B; Martínez MT; Hernando C; Bermejo B; Lluch A; Lopes P; Henrique R; Jerónimo C; Cejalvo JM; Eroles P
Int J Mol Sci; 2020 Oct; 21(19):. PubMed ID: 33050096
[TBL] [Abstract][Full Text] [Related]
6. Clinical potential of miR-940 as a diagnostic and prognostic biomarker in breast cancer patients.
Liu W; Xu Y; Guan H; Meng H
Cancer Biomark; 2018; 22(3):487-493. PubMed ID: 29843213
[TBL] [Abstract][Full Text] [Related]
7. Changes in serum levels of miR-21, miR-210, and miR-373 in HER2-positive breast cancer patients undergoing neoadjuvant therapy: a translational research project within the Geparquinto trial.
Müller V; Gade S; Steinbach B; Loibl S; von Minckwitz G; Untch M; Schwedler K; Lübbe K; Schem C; Fasching PA; Mau C; Pantel K; Schwarzenbach H
Breast Cancer Res Treat; 2014 Aug; 147(1):61-8. PubMed ID: 25086636
[TBL] [Abstract][Full Text] [Related]
8. Serum microRNA-365 in combination with its target gene TTF-1 as a non-invasive prognostic marker for non-small cell lung cancer.
Liu Y; Zhang G; Li H; Han L; Fu A; Zhang N; Zheng Y
Biomed Pharmacother; 2015 Oct; 75():185-90. PubMed ID: 26337230
[TBL] [Abstract][Full Text] [Related]
9. Identification of recurrence-related microRNAs in the bone marrow of breast cancer patients.
Ota D; Mimori K; Yokobori T; Iwatsuki M; Kataoka A; Masuda N; Ishii H; Ohno S; Mori M
Int J Oncol; 2011 Apr; 38(4):955-62. PubMed ID: 21271219
[TBL] [Abstract][Full Text] [Related]
10. Tumor-infiltrating lymphocytes, tumor characteristics, and recurrence in patients with early breast cancer.
Kim ST; Jeong H; Woo OH; Seo JH; Kim A; Lee ES; Shin SW; Kim YH; Kim JS; Park KH
Am J Clin Oncol; 2013 Jun; 36(3):224-31. PubMed ID: 22495453
[TBL] [Abstract][Full Text] [Related]
11. Downregulation of miR-129 in peripheral blood mononuclear cells is a diagnostic and prognostic biomarker in prostate cancer.
Xu S; Yi XM; Zhou WQ; Cheng W; Ge JP; Zhang ZY
Int J Clin Exp Pathol; 2015; 8(11):14335-44. PubMed ID: 26823749
[TBL] [Abstract][Full Text] [Related]
12. Role of miR-139 as a surrogate marker for tumor aggression in breast cancer.
Dai H; Gallagher D; Schmitt S; Pessetto ZY; Fan F; Godwin AK; Tawfik O
Hum Pathol; 2017 Mar; 61():68-77. PubMed ID: 27864119
[TBL] [Abstract][Full Text] [Related]
13. Circulating microRNA-based screening tool for breast cancer.
Frères P; Wenric S; Boukerroucha M; Fasquelle C; Thiry J; Bovy N; Struman I; Geurts P; Collignon J; Schroeder H; Kridelka F; Lifrange E; Jossa V; Bours V; Josse C; Jerusalem G
Oncotarget; 2016 Feb; 7(5):5416-28. PubMed ID: 26734993
[TBL] [Abstract][Full Text] [Related]
14. miRNA expression in breast cancer varies with lymph node metastasis and other clinicopathologic features.
Wang B; Li J; Sun M; Sun L; Zhang X
IUBMB Life; 2014 May; 66(5):371-7. PubMed ID: 24846313
[TBL] [Abstract][Full Text] [Related]
15. Poor prognosis of single hormone receptor- positive breast cancer: similar outcome as triple-negative breast cancer.
Bae SY; Kim S; Lee JH; Lee HC; Lee SK; Kil WH; Kim SW; Lee JE; Nam SJ
BMC Cancer; 2015 Mar; 15():138. PubMed ID: 25880075
[TBL] [Abstract][Full Text] [Related]
16. MicroRNA-9 is associated with epithelial-mesenchymal transition, breast cancer stem cell phenotype, and tumor progression in breast cancer.
Gwak JM; Kim HJ; Kim EJ; Chung YR; Yun S; Seo AN; Lee HJ; Park SY
Breast Cancer Res Treat; 2014 Aug; 147(1):39-49. PubMed ID: 25086633
[TBL] [Abstract][Full Text] [Related]
17. MiR-4728-3p could act as a marker of HER2 status.
Li H; Zhou X; Zhu J; Cheng W; Zhu W; Shu Y; Liu P
Cancer Biomark; 2015; 15(6):807-14. PubMed ID: 26406406
[TBL] [Abstract][Full Text] [Related]
18. Identification of circulating microRNA signatures for breast cancer detection.
Chan M; Liaw CS; Ji SM; Tan HH; Wong CY; Thike AA; Tan PH; Ho GH; Lee AS
Clin Cancer Res; 2013 Aug; 19(16):4477-87. PubMed ID: 23797906
[TBL] [Abstract][Full Text] [Related]
19. Serum microRNA-21 expression as a prognostic and therapeutic biomarker for breast cancer patients.
Yadav P; Mirza M; Nandi K; Jain SK; Kaza RC; Khurana N; Ray PC; Saxena A
Tumour Biol; 2016 Nov; 37(11):15275-15282. PubMed ID: 27696295
[TBL] [Abstract][Full Text] [Related]
20. Screening of miRNAs associated with lymph node metastasis in Her-2-positive breast cancer and their relationship with prognosis.
Qiao EQ; Yang HJ; Zhang XP
J Zhejiang Univ Sci B; 2020 Jun; 21(6):495-508. PubMed ID: 32478495
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
